Difference between revisions of "Part:BBa K3365001:Design"

(→‎References)
Line 19: Line 19:
 
[1]You Lu,Jianxin Xue,Tony Mok et al.Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer[J]. Nature Medicine,2020,26(5):732-740.
 
[1]You Lu,Jianxin Xue,Tony Mok et al.Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer[J]. Nature Medicine,2020,26(5):732-740.
  
−
[2]Wenyan Jiang,David Bikard,David Cox,Feng Zhang,Luciano A Marraffini1.RNA-guided editing of bacterial genomes using CRISPR-Cas systems[J].
+
[2]David Bikard,Wenyan Jiang,Poulami Samai,Ann Hochschild,Feng Zhang,Luciano A. Marraffini1.Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system[J]. Nucleic Acids Research,2013,41(15):7429-7437.
−
Nature Biotechnology,2013,31(3):233-239.
+

Revision as of 09:46, 25 October 2020


Target binding site for dCas9 and subnit Omega


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 66
    Illegal NheI site found at 89
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

We chose a weak promoter for our report protein to enhance the effects of the transcirption activator.


Source

PDCD1 comes from human genome, which is coding for Programmed cell death protein 1

References

[1]You Lu,Jianxin Xue,Tony Mok et al.Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer[J]. Nature Medicine,2020,26(5):732-740.

[2]David Bikard,Wenyan Jiang,Poulami Samai,Ann Hochschild,Feng Zhang,Luciano A. Marraffini1.Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system[J]. Nucleic Acids Research,2013,41(15):7429-7437.